Importantly, while TP53 mutations or deletions also occur within 47% of lung adenocarcinomas, RPS6KB1 and RPS6KB2 amplification/over-expression occur on the background of either wildtype or mutant TP53. This evidence concerns the gene RPS6KB2 and lung adenocarcinoma.